{"name":"Rophibio, Inc.","slug":"rophibio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Eylea® Solution for intravitreal injection","genericName":"Eylea® Solution for intravitreal injection","slug":"eylea-solution-for-intravitreal-injection","indication":"Neovascular (wet) age-related macular degeneration","status":"phase_3"}]}],"pipeline":[{"name":"Eylea® Solution for intravitreal injection","genericName":"Eylea® Solution for intravitreal injection","slug":"eylea-solution-for-intravitreal-injection","phase":"phase_3","mechanism":"Eylea (aflibercept) binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.","indications":["Neovascular (wet) age-related macular degeneration","Macular edema following retinal vein occlusion","Diabetic macular edema","Diabetic retinopathy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiQkFVX3lxTE1sMEMycWZGcDU1SFBwNmx5VnZicW1jYmJlX0pTQ1NmN1gwTzlPQkplZTlldjd5WGJvSFV3ekFXUEFOdw?oc=5","date":"2025-07-22","type":"patent","source":"코메디닷컴","summary":"Daewoong Pharmaceutical Enters Biosimilar Race with Dupixent Candidate as First Pipeline - 코메디닷컴","headline":"Daewoong Pharmaceutical Enters Biosimilar Race with Dupixent Candidate as First Pipeline - 코메디닷컴","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOSTNXM3cydjNwbmJXOHYwNGMzUU4yT2kwQ21ndVlRNFFteUhTakxzYVlrUGdmM01iZUFQLURLQjZFZzU3YmEwN1Nnclh0TEgwejhDUGFPYXpfRTlCWTFWTTJyQjJBTW1WbGxDekpHZnVRaGYyWnZ0aUpMUkN5QW00RlZNdmNUTjlWaUpoT25HZlJKWDBYRHc?oc=5","date":"2024-10-04","type":"pipeline","source":"SeeNews","summary":"N. Macedonia's Alkaloid to invest $1 mln in S. Korea's Rophibio - SeeNews","headline":"N. Macedonia's Alkaloid to invest $1 mln in S. Korea's Rophibio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxORlRxYVBSeE9iVkZreEtZbkdqM0pSRVFyMHBnTWROcndnUDVQVlFPZ0ZFNXZGWnZhMkdoR1ZJT1k1VkVOY2hZOGhXUWx0cXZ5Vy1tcS13aGJHMlJxdUpranlzdEFiTFBnWWtMb3VGaFZQVUlqLWRCZ0l3T3N4bDdjemJzenVFSXdxRDJISVV0MUJnbWtKbjd5emVPbnY3dGo5Nlg0?oc=5","date":"2024-04-12","type":"patent","source":"BioWorld News","summary":"Samsung Bioepis wins nod for Korea’s first Stelara biosimilar - BioWorld News","headline":"Samsung Bioepis wins nod for Korea’s first Stelara biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1EWEtOS0k3T2FHaHlYd01rdXNlTHU5Z0hhemNoREQ4bUJ6RndzR1B6aGVlcVViZ3hlY0xnTFYzb2ZBQV9BVWZ4ZDNjakJnN0tXOVJJMkNWZUpRUm5QWjVYLVlVMEtHbnBVRENyUl930gFyQVVfeXFMTndtUGlaVTIyY1h5OWMyb1gxWHZuMEU2cG9hcG1jMHViazZUWHZBdFBVaEVmdkNWaW00MHpuZnh2Z0ZUUmVWMUx2QkNtTkt0NjhEV1plUmlDOGVpUnhtZjRaQXNBN2pBU1VtdTF1MkFPZjln?oc=5","date":"2024-03-27","type":"patent","source":"koreabiomed.com","summary":"Rophibio begins developing manufacturing process for Keytruda biosimilar - koreabiomed.com","headline":"Rophibio begins developing manufacturing process for Keytruda biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNVWJCMWZqaTVwcnhNdUtjWDJGNnBWSm4yS096b0dueS1Ga3VJS3JOclM5MUd6Mml5TVpLWEhMRlR6T3hhQkxDNV9QM2JQVVFDUC01V1VlN21OVVJUd1phaS0xWFZWUzBpbDBTb2stRkNXNkhJNGZIOW9rSGFJUy1mcVpCeVh2dXNKSTFwYnh3T2JSV1B0NEtIeTlHSkdLZ0JsWWNYV2I5NkRneTAtWE5zZE1PYjdROFJjOGx2TWVUd0tmMGs?oc=5","date":"2024-03-27","type":"patent","source":"Pearce IP","summary":"Rophibio Enters Development Agreement with Avantor for Keytruda® (pembrolizumab) Biosimilar - Pearce IP","headline":"Rophibio Enters Development Agreement with Avantor for Keytruda® (pembrolizumab) Biosimilar","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}